- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06279351
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
February 26, 2024 updated by: Jianguo Sun, Xinqiao Hospital of Chongqing
- To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application.
- To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
96
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jianguo Sun, doctor
- Phone Number: 023-68774490
- Email: sunjianguo@tmmu.edu.cn
Study Contact Backup
- Name: rui kong, doctor
- Phone Number: 15823688918
- Email: kongruiok@163.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue/cytology and genetic testing;
- Physical state is good: PS 0-2;
- Expected survival of more than 3 months;
- Aged 18-75 years old;
- Have not received systematic chemotherapy before;
- Did not receive cetuximab treatment;
- Liver, kidney and bone marrow functions are basically normal;
- The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks;
- Voluntary participation in the group, good compliance, can cooperate with the experiment observation, and sign the written informed consent.
Exclusion Criteria:
- Patients with severe dysfunction of vital organs (heart, liver, kidney);
- Patients with other malignant tumors;
- Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test);
- In the active phase of acute or chronic infectious diseases;
- People with a clear history of drug allergy or allergic constitution;
- Patients participating in other clinical trials;
- Other conditions in which the patient was considered inappropriate to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test group
Thalidomide+cetuximab+FOLFOX/FOLFIRI
|
Thalidomide+cetuximab+FOLFOX/FOLFIRI
|
No Intervention: control group
cetuximab+FOLFOX/FOLFIRI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ETS
Time Frame: 8 weeks
|
Early tumor shrinkage
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PFS
Time Frame: 1 year
|
1 year
|
ORR
Time Frame: 8 weeks
|
8 weeks
|
DCR
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: rui kong, doctor, Chongqing Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2024
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
December 17, 2023
First Submitted That Met QC Criteria
February 26, 2024
First Posted (Actual)
February 28, 2024
Study Record Updates
Last Update Posted (Actual)
February 28, 2024
Last Update Submitted That Met QC Criteria
February 26, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Anti-Bacterial Agents
- Leprostatic Agents
- Thalidomide
- Cetuximab
Other Study ID Numbers
- Thalicolorectal
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thalidomide+cetuximab+FOLFOX/FOLFIRI
-
Istituto Scientifico Romagnolo per lo Studio e...CompletedMetastatic Colorectal CancerItaly
-
University of SaskatchewanTerminatedMetastatic Gastro-esophageal AdenocarcinomaCanada
-
Merck KGaA, Darmstadt, GermanyMerck Pte. Ltd., SingaporeCompleted
-
Peking University Cancer Hospital & InstituteZhejiang Cancer Hospital; West China Hospital; The First Affiliated Hospital... and other collaboratorsCompletedMetastasis | Colorectal Cancer Stage IVChina
-
Assistance Publique - Hôpitaux de ParisGERCOR - Multidisciplinary Oncology Cooperative GroupCompletedEsophageal Cancer Stage IIIFrance
-
Korea Cancer Center HospitalGachon University Gil Medical Center; The Catholic University of Korea; Gangnam... and other collaboratorsUnknownRectal Cancer | Liver Metastasis | Lung MetastasisKorea, Republic of
-
Sofia Perea, Director Clinical Trials Unit.UnknownColorectal Cancer MetastaticSpain
-
China Medical University, ChinaRecruitingUnresectable or Metastatic Colorectal CancerChina
-
University of Campania "Luigi Vanvitelli"Active, not recruitingMetastatic Colorectal AdenocarcinomaItaly
-
Celyad Oncology SARecruitingUnresectable Metastatic Colorectal CancerBelgium, United States